A Study to Evaluate Mosunetuzumab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis

Recruiting now · Phase 2

Conditions studied: Lupus, Systemic Lupus Erythematosus, Lupus Nephritis

In brief

This study will assess how mosunetuzumab works in people who have systemic lupus erythematosus (SLE) who may or may not also have active lupus nephritis (LN).

Key facts

Study ID: NCT07598396
Run by: Hoffmann-La Roche
People needed: 30
Starts: 2026-05-25
Expected to finish: 2028-08-31
Last updated by the study team: 2026-07-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Diagnosis of SLE for ≥ 6 months as assessed using the 2019 European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) Classification Criteria at screening

You may not qualify if…

Pregnant or breastfeeding, or intention of becoming pregnant during the study or within the time frame in which contraception is required
Treatment with investigational therapy within 30 days or 5 drug-elimination half-lives (whichever is longer) prior to initiation of study treatment and during the study
Major surgery requiring hospitalization during the 4 weeks prior to screening or during screening, or any planned surgery or procedure requiring hospitalization during the 12 weeks following study drug administration
Alcohol or substance abuse within the 12 months prior to screening
Active infection of any kind, excluding fungal infection of the nail beds
Any major episode of infection as defined by the protocol
History of serious recurrent or chronic infection
History of progressive multifocal leukoencephalopathy (PML)
Tuberculosis (TB) infection
History of cancer, including solid tumors, hematological malignancies, and carcinoma in situ, within the past 5 years
Active overlap syndrome with mixed connective tissue disease or systemic sclerosis within the 12 months prior to screening or during screening
Catastrophic or severe antiphospholipid syndrome within the 12 months prior to screening or during screening. Antiphospholipid syndrome adequately controlled by anticoagulant therapy for at least 2 months prior to screening is acceptable
High risk for clinically significant bleeding or any condition requiring plasmapheresis, IV immunoglobulin, or acute blood product transfusions
Active severe or unstable lupus-associated neuropsychiatric disease or where, in the opinion of the investigator, it is likely to require treatment with protocol-disallowed therapies. Examples of neuropsychiatric SLE manifestations include, but are not limited to the following: meningitis, retinitis, cerebral vasculitis, myelopathy, demyelination syndromes, acute confusional state, psychosis, acute stroke or stroke syndrome, cranial neuropathy, status epilepticus or seizures, cerebellar ataxia, and mononeuritis multiplex
History of any non-SLE disease treated with oral, intravenous, or intramuscular corticosteroids for more than 14 days in total during the one year prior to Day 1
History of treatment with any T cell-engaging bispecific antibodies or CAR-T therapy within the past 2 years
Receipt of any live or attenuated vaccine in the 28 days prior to or during screening

Where it is running

Clnica SER da Bahia — Salvador, Estado de Bahia, Brazil (enrolling)
L2IP ?Instituto de Pesquisas Clínicas Ltda. — Brasília, Federal District, Brazil (enrolling)
IPC MT Instituto de Pesquisas Clinicas do Mato Grosso — Cuiab, Mato Grosso, Brazil (enrolling)
Complexo Hospitalar de Niteroi — Niterói, Rio de Janeiro, Brazil (enrolling)
LMK Servios Mdicos S/S Ltda — Porto Alegre, Rio Grande do Sul, Brazil (enrolling)
Hospital das Clinicas de Ribeirao Preto — Ribeiro Preto, São Paulo, Brazil (enrolling)
Hospital das Clnicas da Faculdade de Medicina da USP — São Paulo, São Paulo, Brazil (enrolling)
Clinica de la Costa S.A.S — Barranquilla, Colombia (enrolling)
Centro de Investigacion en Reumatologia y Especialdades Medicas SAS. CIREEM — Bogotá, Colombia (enrolling)
Hospital Pablo Tobon Uribe — Medellín, Colombia (enrolling)
Fondazione Policlinico Universitario Agostino Gemelli IRCCS — Rome, Lazio, Italy (enrolling)
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (Presidio Spedali Civili) — Brescia, Lombardy, Italy (enrolling)
Centro Medico del Angel — Mexicali, Estado de Baja California, Mexico (enrolling)
Centro de Investigación y Tratamiento Reumatológico S.C. — México, Mexico CITY (federal District), Mexico (enrolling)
Emmed Research — Pretoria, Gauteng, South Africa (enrolling)
University of Cape Town Kidney and Hypertension Research Unit — Cape Town, Western Cape, South Africa (enrolling)
Clinical Trials Network Helderberg — Somerset West, Western Cape, South Africa (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.